Abu Dhabi Startup Ovasave Raises $1.2M to Expand Fertility Platform

Abu Dhabi-based FemTech startup Ovasave has secured $1.2 million in pre-seed funding to scale its digital health platform across the GCC. The round was led by PlusVC, Annex Investments, and New York’s 25 Madison, with additional support from strategic angel investors and family offices in the UAE and Saudi Arabia.

Founded in 2023, Ovasave focuses on fertility and hormonal health, offering a digital-first service for hormone testing, egg freezing, virtual consultations, and menopause care. Its platform combines at-home diagnostic tools with personalised care protocols and access to fertility clinics. The company also runs a corporate benefits programme, aimed at helping organisations offer reproductive health services as part of employee wellbeing strategies.

"There is a critical need for timely intervention in women’s health, particularly around fertility and hormonal health, Torkia Mahloul, Co-founder and CEO of Ovasave said. "This funding marks a crucial step in our mission to disrupt women’s health and expand access to fertility and hormonal care across the region.

A recent report by FemTech Analytics showed that the FemTech market in the region is projected to reach $3.8 billion by 2031, growing at a CAGR of 15% from 2021 to 2031. The new capital will support Ovasave’s regional expansion, the scaling of employer partnerships, and the development of the next version of its mobile app. Upcoming features will include menstrual cycle tracking, symptom monitoring, AI-supported treatment recommendations, and expanded menopause support.

Ovasave is registered with the Department of Health – Abu Dhabi and is part of the Hub71 tech ecosystem, aligning its services with national efforts to digitise healthcare and expand access to preventive care.